Abstract: A pharmaceutical iodophor preparation having predictable microbicidal effectiveness and long duration of action comprising polyvinylpyrrolidone-iodine (PVPI), free iodine, a source of iodide ions and a source of iodate ions, the preparation having a ratio of available (titratable) iodine to iodide between 2:1 and 10:1, a pH between 5 and 6 and a free iodine concentration between 2 and 20 ppm, wherein the amount of iodate ion in the preparation is sufficient to maintain the free iodine concentration between 2 and 20 ppm for at least 12 months at 20.degree. C.

Abstract: Antihypertension action is achieved without diuresis by administration of a thiazide diuretic in an amount which while being sufficient to achieve antihypertension is insufficient to achieve diuresis. Such administration in a non-diuretic amount is effected in 4-8 consecutive hourly doses to achieve reduction of blood pressure without high urine output. The invention further relates to complexes of thiazides with mixed cation-anion exchange resins, to insoluble basic metal hydroxy thiazide salts, the salts of thiazide with calcium disodium edetate or disodium edetate, to molecular complexes of thiazides with long chain polymers such as hydroxy alkyl cellulose polymers, carboxy methyl cellulose and polyvinylpyrrolidone, to beta-adrenergic blocking amine-thiazide salts and to amiloride thiazide salts.

Abstract: A preparation for percutaneous administration of nitroglycerine, said preparation comprising nitroglycerine incorporated in a cream base in an amount not less than about 0.05% by weight based on the total weight of the preparation. The composition may also contain other medicaments, the bioavailability of which is enhanced by the nitroglycerine. The action of the preparation against for example angina may be brought about by having an appropriate amount of nitroglycerine or as additional medicament another medicament active against angina. The preparation may contain an hydroxyalkylcellulose which may provide, in combination with a waxy component in the cream, for example a higher aliphatic alcohol, a prolonged release effect. The preparation has advantages particularly as regards bioavailability over prior uniphasic ointments.

Abstract: Sterilized povidone-iodine (polyvinylpyrrolidone-iodine) is obtained by irradiating povidone-iodine in the presence of iodide ions. Preferably the irradiation is effected in the presence of iodine and both iodide and iodate ions. The iodide ions, with or without iodate ions, have the effect of preventing the degradation of povidone-iodine and the gelation of iodine and povidone.

Abstract: A preparation for percutaneous administration of nitroglycerine, said preparation comprising nitroglycerine incorporated in a cream base in an amount not less than about 0.05% by weight based on the total weight of the preparation. The composition may also contain other medicaments, the bioavailability of which is enhanced by the nitroglycerine. The action of the preparation against for example angina may be brought about by having an appropriate amount of nitroglycerine or as additional medicament another medicament active against angina. The preparation may contain an hydroxyalkylcellulose which may provide, in combination with a waxy component in the cream, for example a higher aliphatic alcohol, a prolonged release effect. The preparation has advantages particularly as regards bioavailability over prior uniphasic ointments.

Abstract: Choline salicylate sulfite and choline salicylate alkali metal sulfite-containing compounds of the formula, ##STR1## WHEREIN Me represents the sodium, potassium or lithium ion and R represents the sulfite, bisulfite, metabisulfite, dithionate, hydrosulfite and hyposulfite groups are described. Said compounds are stable and inhibit the formation of color in pharmaceutical preparations containing the same. The method for the preparation of choline salicylate sulfite and choline salicylate alkali metal sulfite-containing compounds, and pharmaceutical dosage forms containing the same are disclosed together with a method for their use to inhibit color formation.

Abstract: Alkyl esters of aminosalicylic acid, said alkyl group having from 1 to 18 carbon atoms in chain length; alkenyl esters of aminosalicylic acid, said alkenyl group selected from the group consisting of vinyl, allyl, undecenyl, oleyl and linolenyl groups, and cyclic esters of aminosalicylic acid, said cyclic group being the cyclohexyl, phenyl and menthyl groups, having ultra-violet screening properties to absorb light rays within the wave-length range of 2950 A. to 3200 A. while transmitting the light rays beyond the 3200 A. range to permit the desirable tanning of the skin without solar burn. The respective esters of aminosalicylic acid are prepared by the reduction of the appropriate nitro-salicylic acid ester with Raney nickel and hydrogen in the presence of ethyl acetate. The respective esters are obtained as oils or solid crystalline substances and are soluble in alcohols, chloroform, acetone and benzene but insoluble in water. The ultra-violet absorption spectra for the respective compounds are described.

Abstract: Choline salicylate sulfite and choline salicylate alkali metal sulfite-containing compounds of the formula, ##STR1## wherein Me represents the sodium, potassium or lithium ion and R represents the sulfite, bisulfite metabisulfite, dithionate, hydrosulfite and hyposulfite groups are described. Said compounds are stable and inhibit the formation of color in pharmaceutical preparations containing the same. The method for the preparation of choline salicylate sulfite and choline salicylate alkali metal sulfite-containing compounds, and pharmaceutical dosage forms containing the same are disclosed together with a method for their use to inhibit color formation.

Abstract: Choline salicylate sulfite and choline salicylate alkali metal sulfite-containing compounds of the formula, ##SPC1##Wherein Me represents the sodium, potassium or lithium ion and R represents the sulfite, bisulfite, metabisulfite, dithionate, hydrosulfite and hyposulfite groups are described. Said compounds are stable and inhibit the formation of color in pharmaceutical preparations containing the same. The method for the preparation of choline salicylate sulfite and choline salicylate alkali metal sulfite-containing compounds, and pharmaceutical dosage forms containing the same are disclosed together with a method for their use to inhibit color formation.